GH vs NTRA
GH: Guardant Health is a leader in precision oncology, utilizing advanced liquid biopsy technology to provide comprehensive genomic insights across the cancer care continuum. NTRA: Natera is a pioneer in cell-free DNA testing, providing advanced genetic insights across prenatal, oncology, and organ health applications.
Side-by-side fundamentals
| Metric | GH | NTRA | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $162.59 | $405.92 | |
| Market cap | $21.8B | $58.5B | |
| Net margin FY2025, SEC XBRL | -42.4% | -9.0% | NTRA higher |
| Operating margin FY2025, SEC XBRL | -44.5% | -13.4% | NTRA higher |
| ROE FY2025, SEC XBRL | n/a | -12.2% | |
| ROA FY2025, SEC XBRL | -20.7% | -8.7% | NTRA higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 0.04 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +32.9% | +35.9% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +29.8% | +41.1% | NTRA higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.23 | 1.29 | |
| 1-year return as of 2026-10-20 close | +131.6% | +115.2% | GH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.